@FiercePharma: EMA pulls Avandia; FDA restricts use. Article | Follow @FiercePharma
> European regulators are reviewing the benefits of using Roche's top-selling Avastin drug in breast cancer, in light of fresh clinical trial results; the review comes as FDA is also reconsidering the indication. Report
> There is no evidence to link GlaxoSmithKline's H1N1 swine flu vaccine Pandemrix to cases of narcolepsy, European regulators said, but a full review is needed and will take three to six months. Report
> Breast cancer rates among postmenopausal women in Canada dropped nearly 10 percent after a 2002 study that found taking hormone replacement therapy could increase cancer risk, researchers said. Report
> Royal DSM is in talks with potential Chinese and Indian partners for its penicillin unit in a bid to boost Asian sales and revive profitability, CEO Feike Sijbesma said in an interview. Report
> Goldman Sachs is very bullish on Mylan even though many investors are skeptical about a stock that has declined by 20 percent in the past six months. Report
> Pharmacists and other health-care practitioners say ongoing drug shortages are accompanied by difficulties including a lack of available information, trouble finding alternative medications, and deadly errors. Report
Biotech News
@FierceBiotech: Third Rock leads $30M round for antibody upstart. Article | Follow @FierceBiotech
@JohnCFierce: AstraZenceca/Rigel RA drug (subject of a $1.2B pact) gets promising data in IIb. Item | Follow @JohnCFierce
> AZ, BMS drug dapagliflozin supports weight loss. Story
> EU regulators rebuff Merck KGaA on MS drug. Article
> Alnylam announces 25-30% reduction of workforce. Item
> AZ gets positive opinion for heart drug in EU. News
> FDA accepts CMC plan for lead Bionovo drug. Story
And Finally... The rise in ADHD diagnoses indicates one of two things: either children are more fidgety and less able to focus these days, or parents and doctors are less patient with the squirms and jiggles of childhood. Report